Adoptive T cell immunotherapy with genetically engineered T cells has shown promise in multiple trials in which an antigen receptor of sufficient affinity was used to target a tumor-associated antigen, including antibody-based chimeric receptors 1-3 and high-affinity TCRs 4-8 . However, isolating an effective TCR within the affinity limits imposed by central tolerance remains a substantive roadblock to implementing this approach for the diversity of malignancies in which candidate intracellular self/tumor antigens have been identified 9,10 . Therefore, enhancing the affinity of tumor-specific TCRs beyond the limits of negative selection represents a strategy for creating TCR reagents that have greater potential for achieving tumor eradication, and this may be essential for tumors that commonly downregulate MHC class I and thus present limited amounts of the targeted antigen 11 .
A r t i c l e s Adoptive T cell immunotherapy with genetically engineered T cells has shown promise in multiple trials in which an antigen receptor of sufficient affinity was used to target a tumor-associated antigen, including antibody-based chimeric receptors 1-3 and high-affinity TCRs [4] [5] [6] [7] [8] . However, isolating an effective TCR within the affinity limits imposed by central tolerance remains a substantive roadblock to implementing this approach for the diversity of malignancies in which candidate intracellular self/tumor antigens have been identified 9, 10 . Therefore, enhancing the affinity of tumor-specific TCRs beyond the limits of negative selection represents a strategy for creating TCR reagents that have greater potential for achieving tumor eradication, and this may be essential for tumors that commonly downregulate MHC class I and thus present limited amounts of the targeted antigen 11 .
Methods have been developed to enhance the affinity of TCRs intended for use in TCR gene therapy 10, [12] [13] [14] . These approaches generally employ saturation mutagenesis targeting the complementarity-determining regions (CDRs) that interact predominantly with peptide (CDR3) and/or MHC (CDR1 and/or CDR2) 15 . Mutations in CDR1 or CDR2 theoretically pose a greater risk in the clinic because changes to MHC contact residues can increase TCR affinity for MHC independent of peptide, reducing specificity and selectivity for the cognate peptide antigen 16, 17 . CDR1 and CDR2 mutations can also alter the docking geometry of the TCR-MHC interaction 18 , further increasing risk for cross-reactivity. This notion was highlighted in a recent clinical trial, in which T cells expressing an enhanced affinity TCR containing CDR2 mutations mediated rapid and fatal toxicity from unpredicted cross-reactivity with a nonamer epitope from a self-antigen expressed in the heart, despite being disparate at four of seven non-anchor residues 19, 20 . Although limiting mutations to the CDR3 region may reduce unpredicted cross-reactivities in vivo, current methodologies targeting specific CDR3 residues for amino acid substitution generally yield libraries with diversity constrained by the unaltered length of the parental CDR3 sequence. By contrast, the natural process of diversity generation in the thymus employs recombination activating gene (RAG)-mediated TCR gene rearrangements to generate highly diverse CDR3s varying in length as well as amino acid composition. Therefore, greater CDR3 diversity with retention of specificity might be accessed by harnessing the V(D)J recombination machinery active during T cell development.
TCR gene rearrangement begins at the earliest stages of murine T cell development, before CD4 and CD8 expression, at the loci that encode the TCRβ, TCRγ and TCRδ chains. Rearrangement at the Tcra locus is restricted to the CD4 + CD8 + double-positive (DP) stage, which occurs later. This delayed Tcra gene rearrangement plays a central role in dictating γδ versus αβ T cell fate, which is determined by the strength of TCR signals at the CD4 − CD8 − CD44 − CD25 + doublenegative 3 (DN3) stage. A functional TCRβ chain paired with the invariant pre-Tα chain provides a weak signal that promotes αβ lineage commitment (referred to as β-selection) 21 ; rearrangement and expression of TCRγ and TCRδ chains can lead to stronger signals that drive γδ lineage commitment 22 .
In most transgenic mice expressing an αβ TCR, TCRα expression is not delayed, and as a result a population of mature TCRαβ + DN T cells are often found in the thymus and periphery, which are Generation of higher affinity t cell receptors by antigen-driven differentiation of progenitor t cells in vitro Many promising targets for T-cell-based cancer immunotherapies are self-antigens. During thymic selection, T cells bearing T cell receptors (TCRs) with high affinity for self-antigen are eliminated. The affinity of the remaining low-avidity TCRs can be improved to increase their antitumor efficacy, but conventional saturation mutagenesis approaches are labor intensive, and the resulting TCRs may be cross-reactive. Here we describe the in vitro maturation and selection of mouse and human T cells on antigenexpressing feeder cells to develop higher-affinity TCRs. The approach takes advantage of natural Tcrb gene rearrangement to generate diversity in the length and composition of CDR3b. In vitro differentiation of progenitors transduced with a known Tcra gene in the presence of antigen drives differentiation of cells with a distinct agonist-selected phenotype. We purified these cells to generate TCRb chain libraries pre-enriched for target antigen specificity. Several TCRb chains paired with a transgenic TCRa chain to produce a TCR with higher affinity than the parental TCR for target antigen, without evidence of cross-reactivity.
A r t i c l e s thought to represent 'γδ-wannabe' cells that develop aberrantly as a result of strong signals delivered through the transgenic αβ TCR at the DN3 stage 23, 24 . This population does not develop when the transgenic TCRα is expressed only after β-selection 25 , and it is more pronounced in transgenic mice expressing a TCR specific for a selfantigen (for example, male mice with a TCR specific for the male HY antigen have substantially more TCRαβ + DN T cells than do female littermates 24, 26 ). This suggests that in TCR-transgenic animals, the TCRαβ + DN T cell population represents a distinct population of agonist-selected T cells, and that stronger agonist signals before βselection promote the development of this lineage.
These findings suggest that TCR affinity could be enhanced by recapitulating this process in vitro using hematopoietic progenitor cells (HPCs) that ectopically express only the TCRα chain from a target-antigen-specific TCR before β-selection. HPCs can be induced to expand and differentiate into T lineage cells on OP9-DL1 cells 27, 28 , generating a large pool of progenitor T cells with unique, naturally occurring Tcrb gene rearrangements. We hypothesized that, when these progenitors are differentiated in the presence of cognate antigen, those expressing a TCRβ chain that confers high affinity for the target antigen when paired with the TCRα chain will be diverted to a DN TCRαβ + lineage. These agonist-selected cells could then be isolated to identify endogenous TCRβ chains that produce the highest-affinity antigen-specific TCRs.
RESULTS

Development of phenotypically mature DN TCRab + T cells
To determine whether progenitor thymocytes from mice expressing an αβ TCR also differentiate into DN TCRαβ + cells in vitro in response to cognate antigen, TCRαβ − CD4 − CD8 − CD117 + CD44 + (DN1/DN2) progenitor thymocytes were sorted from ovalbumin (OVA)-specific TCR-transgenic OT1 mice and cultured on OP9-DL1 cells expressing H-2K b and H-2D b (OP9-K b D b DL1) either in the absence of peptide or with increasing concentrations of the OVA peptide SIINFEKL. In the absence of peptide, DP T cells were detected at day 16, and they constituted a major fraction of the cell culture by day 20, as previously reported 28, 29 . However, development and/or survival of DP T cells was diminished by even very low concentrations of SIINFEKL peptide (0.0001 µM), and DP cells were completely absent from cultures containing 0.01 µM or more of the peptide (Fig. 1a) , suggesting that DP cells fail to develop or are negatively selected by strong agonist signaling in OP9-K b D b DL1 cultures, as observed in vivo 30 . On day 5, the majority of cells displayed an immature TCRβ − CD24 + phenotype (Fig. 1b) , but by day 16 most DN cells from all culture conditions expressed TCRβ, with more TCRβ + CD24 − cells detected for those exposed to the higher peptide concentrations. By day 20, ~60% of all DN cells from cultures containing 0.01 µM or 1.0 µM peptide were TCRβ + CD24 − , whereas in cultures that received no or very low concentration (0.0001 µM) of peptide, only ~20% of DNs were TCRβ + CD24 − , and ~50% were TCRβ − and likely of NK lineage ( Fig. 1b,c) . Furthermore, DN TCRβ + cells that developed in response to high peptide concentrations expressed higher levels of cell surface TCRβ, consistent with a more mature phenotype (Fig. 1c) . High concentrations of SIINFEKL, but not of the positive-selecting antagonist peptide EIINFEKL (E1) 30 , led to greater absolute numbers of DN TCRβ + T cells ( Fig. 1d) , indicating that more avid TCR signaling enhances the development of this population. This effect appears to plateau at very high concentrations of peptide, above 0.1 µM. To confirm that TCRαβ + DN cells observed in these cultures did not develop by passing through a DP stage, pre-selection CD69 − DP T cells were sorted from the thymus of wild-type C57BL/6 (B6) or OT1 TCR-transgenic mice and cultured on OP9-K b D b DL1 cells in the presence or absence of SIINFEKL peptide (Supplementary Fig. 1 ). Whereas B6 DP cells were not affected by the presence of SIINFEKL peptide, OT1 DP thymocytes cultured in the presence of SIINFEKL exhibited the hallmarks of negative selection, including CD4 and CD8 co-receptor downmodulation and loss of cellularity 31 , and DN TCRβ + cells were not detected.
Generation of agonist-selected TCRb chains in vitro
We sorted DN1 and DN2 thymocytes (TCRαβ − CD4 − CD8 − CD117 + CD44 + ) from B6 mice and retrovirally transduced them with a vector containing the extracellular domain of human CD2 (hCD2) to track transduced cells along with the TCRα chain 3D-PYYα from a previously described H-2D b -restricted TRBV4 (Vβ10)/TRAV9-1 TCR specific for the WT1 tumor antigen RMFPNAPYL epitope and affinity-enhanced by saturation mutagenesis of CDR3α 32, 33 . Transduced progenitor thymocytes were cultured on OP9-K b D b DL1 cells in the presence or absence of 1.0 mM RMFPNAPYL for 14 d. DN cells within the untransduced hCD2 negative fraction contained <2% TCRαβ + cells, regardless of the presence of the WT1 peptide in the culture. In contrast, the DN fraction from the transduced hCD2 + population on day contained 6.8% TCRβ + cells in the absence of peptide, and 16.6% if 1 µM WT1 peptide was added ( Fig. 2a) .
We expected a fraction of these cells to recognize the WT1 peptide, but could not detect WT1 tetramer + DN cells, because of either a lack of CD8 expression, lower TCR surface levels, or low frequency. Therefore, we generated a library of TCRβ chains from the DN TCRβ + population that develops from 3D-PYYα-transduced HPCs cultured on OP9-K b D b DL1 with peptide, to identify TCRβ chains that confer WT1 tetramer binding when paired with 3D-PYYα ( Fig. 2b) . Sequences from >30 clones were analyzed, and the top four TCRβ chains by frequency were advanced for further study. All these clones had CDR3β sequences that shared multiple residues with the parental 3Dβ chain ( Fig. 2c) , with clone #1 almost identical to the original 3Dβ ( Fig. 2c and Supplementary Fig. 3 ). The four candidate TCRβ chains were retrovirally transduced into endogenous Tcra/Tcrb-genedeficient 58 −/− 3D-PYYα cells and analyzed by flow cytometry (Fig.  2d ). All four TCRs bound tetramer, although clone #4, which exhibited the weakest homology to the original 3D CDR3β, bound tetramer at substantially lower levels and was not analyzed further.
The approximate relative affinity for tetramer of two of the three candidate TCRβ chains, when paired with 3D-PYYα, was higher than that of the original 3Dβ, with clone #1 having >3-fold higher affinity ( Fig. 3a and Online Methods). To more accurately compare tetramer staining of 3D-PYYα clone #1 TCRβ versus the original 3Dβ, clone #1 was codon-optimized such that the only sequence differences between the original 3Dβ and clone #1 were in the CDR3 region. As expected, transduced T cells expressing the clone #1 TCRβ chain at similar levels to the parental 3Dβ chain exhibited enhanced tetramer staining ( Fig. 3b) . Clone #1 transduced 58 −/− 3D-PYYα cells were stained with a panel of H-2D b -tetramers containing alternative peptides, and no staining could be detected using other peptide-H-2D b tetramers ( Fig. 3c ), suggesting the increased affinity observed for these receptors is not the result of increased affinity for MHC alone.
TCRb + DN cells develop in the thymus of TCRa retrogenic mice WT1 is expressed in the thymus 34, 35 , and we wanted to determine whether a similar selection process would occur during thymic development in vivo in mice. In mice, agonist-selected T cells may accumulate throughout the life of the animal, allowing a broader repertoire of TCRs reactive to this self-antigen to be assessed. Therefore, we generated A r t i c l e s TCRα retrogenic mice by transferring 3D-PYYα-transduced hematopoietic stem cells (HSCs) into irradiated recipient mice 36 . A substantially increased population of DN TCRβ + cells was detected among 3D-PYYα-transduced thymocytes and splenocytes as compared to untransduced controls ( Fig. 4a) . Furthermore, these thymocytes contained an increased proportion of T cells expressing the Vβ10 gene used by the original 3Dβ ( Fig. 4a ), suggesting that at least some DN TCRβ + cells might be specific for the same WT1 antigen.
We generated Vβ10-Cβ1 and Vβ10-Cβ2 libraries from DN TCRαβ + cells (Fig. 4b ) enriched for binding to WT1 tetramer ( Supplementary  Fig. 2 and Online Methods) and recovered TCRβ chains ( Fig. 4c) . Three dominant clones were analyzed ( Fig. 4d) , with Thyβ#1 showing enhanced tetramer binding compared to 3Dβ, while Thyβ#2 and Thyβ#3 appeared to have similar or slightly lower affinity than 3Dβ, respectively. TCR 3D-PYYα-Thyβ1 exhibited enhanced affinity compared to T cells expressing 3D-PYYα-3Dβ ( Fig. 4e) , and enhanced interferon γ (IFNγ) production in response to peptide-pulsed target cells ( Fig. 4f,g) . Thyβ#1 differs from the original 3Dβ chain by only one amino acid at position 108 ( Fig. 4b) , which is one of the two positions for which clone #1 from the OP9-DL1-derived TCRβ library screen differed from 3Dβ ( Fig. 2c and Supplementary Fig. 3 ), suggesting that the proline at this position in the parental 3Dβ either does not optimally contribute or has a negative impact on peptide binding.
To assess the in vivo safety of the highest-affinity murine TCRs generated, P14 CD8 + T cells were transduced to express codon-optimized, P2A-linked TCR chains (3Dαβ or 3D-PYYα paired with either 3Dβ, in vitro-derived Vβ10 clone #1, or Thyβ#1). We injected the TCRtransduced T cells into C57BL/6 mice and assessed autoimmunity, including weight loss and transgenic T cell expansion. Somewhat decreased numbers were observed for T cells transduced with the enhanced affinity Vβ chains at the late (day 126) time point, perhaps reflecting a moderate increase in peripheral tolerance and/or deletion 37 . Otherwise, no toxicities or differences were observed between these WT1-specific T cells (Supplementary Fig. 4) .
To examine the full TCRβ repertoire of agonist-selected DN TCRαβ + cells, we analyzed DN TCRαβ + thymocytes from 3D-PYYα retrogenic mice by high-throughput sequencing and repertoire analysis 38 (Supplementary Fig. 5 ). We identified 141,113 unique A r t i c l e s TCRβ chain sequences from 1,486,250 reads representing 288,000 sorted cells. The clonality was 0.05, with the most frequent clone representing 0.04% of the total, indicating that this lineage-diverted population is highly diverse, with limited clonal expansion. Only a small percentage of the TCRβ repertoire expressed Vβ10 (TRBV4), and substantial expansion of TRBV17 + cells was observed as compared to total C57BL/6 thymocytes, with 9 of the top 10 most common TCRβ sequences using this Vβ gene. However, screening of diverse rapid amplification of cDNA ends (RACE)-PCR-based libraries revealed that only Vβ10 TCRβ chains were reactive with WT1 (data not shown). Therefore, TCRs incorporating Vβ17 chains are more likely specific for thymus-expressed antigens other than WT1. Thus, restricting TCRβ chain libraries to the parental TCRβ gene should not only increase the frequency of TCRs that bind the target antigen but also minimize the isolation of TCRs with alternative specificities.
Generation of human agonist-selected TCRb chains in vitro
To extend the approach to human specificities, cord-blood-derived CD34 + HPCs were selected and transduced to express the P2Alinked TCRαβ chains of a high-affinity HLA-A2-restricted human TCR specific for WT1 [37] [38] [39] [40] [41] [42] [43] [44] [45] (WT1 37 αβ) and cultured on OP9-DL1 cells expressing HLA-A2 (OP9-A2-DL1) in the presence or absence of WT1 peptide (Supplementary Fig. 6 ). After 22 d, human HPCs transduced with WT1 37 αβ and cultured on OP9-A2-DL1 cells included a substantial population of CD3 + CD4 − CD27 + cells heterogeneous for CD8 (~75% CD8 − ), consistent with γδ lineage cells 39, 40 , which were mostly absent from untransduced controls (Supplementary Fig.  6 ). Addition of cognate WT1 peptide to the cultures increased the proportion of these cells (from 29.6% to 40.2%), suggesting enrichment for agonist-selected T cells. Human CD34 + HPCs were then transduced to express only the TCRα chain of TCR WT1 37 (WT1 37 α) and cultured with OP9-A2-DL1 cells in the presence of cognate WT1 peptide. Compared to untransduced controls, WT1 37 α expressing progenitors contained a greater proportion of CD3 + CD27 + cells, which included a unique population of TCRβ + CD8 − cells within the transduced CD3 + CD27 + subset (Fig. 5a,b) . We sorted CD3 + TCRβ + CD27 + DN and CD3 + TCRβ + CD8 + CD27 hi cells as the populations most likely to contain agonist-selected cells, and generated TCRβ libraries.
As the parental TCRβ chain utilizes TRBV19 (Vβ17), we generated Vβ17-restricted Cβ1 and Cβ2 libraries, as well as separate, more diverse RACE-PCR-derived libraries. The TCRβ libraries were transduced into the CD8 − T cell line H9 previously transduced to express WT1 37 α (H9.WT1 37 α), and Vβ17-library-transduced cells were sorted for Vβ17 expression (Fig. 5c) . We enriched for WT1 tetramer-reactive cells and detected a range of tetramer reactivity after enrichment, suggestive of an enriched pool of TCRβ chains with a range of affinities for HLA-A2/WT1 (Fig. 5c) . We found 26 TCRβ chains detected multiple times, and these were coexpressed in the CD8 − TCRαβdeficient Jurkat76 cell line with WT1 37 α. Of these 26 TCRβ chains, 11 bound WT1 tetramer independent of CD8 when paired with WT1 37 α (Supplementary Fig. 7a ). This group contained three Vβ families, three Jβ families, and CDR3 regions ranging from 13 to 16 amino acids (Supplementary Fig. 7a ). Vβ17 was used by 9 of these 11 TCRs, and 3 Vβ17 + TCRs exhibiting the highest tetramer binding were selected for further study (Fig. 6b) . The TCR with the highest A r t i c l e s apparent affinity, Vβ15#1, was also further analyzed, although TCRs using nonparental Vβ chains would require extensive screening for potential cross-reactivities before being considered for clinical use. Codon-optimized lentiviral constructs (TCRβ-P2A-WT1 37 α) were synthesized for each TCRβ chain and were expressed in Jurkat76 cells (Fig. 6b) . All of the selected TCRβ chains exhibited enhanced tetramer binding compared to the wild-type TCRβ chain when paired with WT1 37 α (Fig. 6c) . We transduced the TCRs into primary human CD8 + T cells and expanded sorted tetramer + CD8 + T cells. Each Vβ17 + TCR expressed similar levels of the transgenic Vβ17 chain, and all transduced populations expressed similar levels A r t i c l e s of CD8 (Supplementary Fig. 8a) . T cells expressing enhanced-affinity TCRs Vβ17#2-P2A-WT1 37 α, Vβ17#3-P2A-WT1 37 α and Vβ15#1-P2A-WT1 37 α exhibited enhanced IFNγ production in response to titrated concentrations of WT1 peptide compared to wild-type Vβ17wt αβ TCR (Fig. 6d) , and none of the TCRs produced IFNγ in the absence of peptide (Supplementary Fig. 8b) . Despite enhanced affinity for WT1 37 tetramer (Fig. 6b,c) , TCR Vβ17#7-P2A-WT1 37 α displayed a diminished functional response to WT1 peptide. As discrepancies have been previously reported between affinity measured by tetramer binding (which occurs in three dimensions) and functional readouts that depend on TCR peptide-MHC interactions at the two-dimensional T cell-antigen-presenting cell interface 41, 42 , these results highlight the necessity for functional screening of candidate TCRs in addition to tetramer-based assays. Taken together, these data demonstrate the utility of this approach for isolating enhanced affinity TCRs specific for human tumor/self-antigens.
DISCUSSION
Here we report on a system for efficiently generating and screening diverse CDR3β chains pre-enriched for specific antigen reactivity from which enhanced affinity TCRs can be isolated. This approach takes advantage of the fact that agonist signaling through a mature TCRαβ complex before the β-selection checkpoint results not in negative selection but rather in T cell differentiation to a distinct DN TCRαβ + lineage with similarities to γδ T cells. Because TCRβ libraries are generated from a population selectively enriched for cells responding to an agonist TCR signal during differentiation, the resulting library requiring analysis for antigen reactivity can be much smaller than the typical saturation mutagenesis libraries commonly used to generate high-affinity TCRs 33, 43, 44 . A major concern for clinical translation of affinity-enhanced TCRs is the risk of off-target T cell activation and autoimmunity. While any modification to the antigen-binding domains of a TCR could potentially lead to off-target toxicity, modifications limited to CDR3 are less likely to influence interactions with MHC independent of peptide 45 . V(D)J recombination at the TRB locus can produce extensive CDR3β diversity in both length and amino acid composition through differential V-D-J gene segment usage, nucleotide deletions and nongermline-encoded N-and P-nucleotide additions at the V-D and D-J junctions. As such, this approach has potential for CDR3 diversity, minimizing the need for improving affinity by additional CDR1 and/or CDR2 mutations. Notably, three of the five enhanced-affinity human TCRβ chains isolated in this study have a longer CDR3 than the parental TCRβ chain ( Fig. 6a and Supplementary Fig. 7) .
One limitation of this system is that it is necessarily restricted to the TCRβ chain. However, this approach can be readily coupled with traditional saturation mutagenesis of TCRα CDR3 regions. Indeed, the mouse 3Dα-PYY TCR used in our study contains affinity-enhancing mutations in CDR3α and, when paired with the parental 3Dβ, Figure 5 Agonist-selection of in vitro-derived human T cells with enhanced affinity for antigen. CD34 + HPCs were purified from umbilical cord blood, lentivirally transduced with WT1 37 α-IRES-GFP and cocultured with the OP9-A2-DL1 cell line in the presence of 1 µg/ml WT1 peptide. (a,b) Untransduced GFP − (a) or WT1 37 α-expressing GFP + cells (b) were analyzed on day 31 of culture for expression of CD3, TCRβ, CD8, and CD27. (c) TCRβ libraries were generated from CD3 + TCRβ + CD27 + DN cells as well as CD3 + TCRβ + CD8 + cells expressing high levels of CD27 present after day 20 of culture. (c) Cβ1 and Cβ2 libraries were generated using a 5′ Vβ17 primer and transduced into H9 cells transduced to express WT1 37 α (H9.WT1 37 α). H9.WT1 37 α cells transduced with Vβ17 libraries were first sorted for Vβ17. All library-transduced cells underwent two rounds of low-stringency tetramer + sorts followed by cell expansion, and then were sorted for tetramer hi cells, from which antigen-specific TCRβ chain genes were cloned for further analysis. A r t i c l e s has been shown to exceed the affinity limits imposed by negative selection 32 . The fact that we could isolate TCRs with affinities that surpassed that of the 3D-PYYαβ TCR affirms that this system can generate TCRs that would normally be excluded from the peripheral T cell repertoire 32 .
Tumor-reactive CD4 + T cells can exhibit potent antitumor activity through recognition of tumor-associated MHC II ligands [46] [47] [48] , but most solid tumors do not express MHC II molecules, limiting the ability of CD4 + T cells to function at the tumor site. However, MHC-I-restricted TCRs with sufficient affinity to bind peptide-MHC and signal independent of a contribution by CD8 can be used to redirect CD4 T cells to recognize MHC-I-presented antigens 49 . Although such TCRs have been naturally isolated 50 , most require higher affinity for peptide-MHC I than is typical for naturally occurring MHC-I-restricted TCRs 49 . The agonist-selected T cells we describe develop in the absence of CD8 (i.e., from DN thymocytes) and may therefore express TCRs that is more likely to function independently of CD8 in mature T cells. In fact, all the enhanced-affinity human WT1-specific TCRs generated bound peptide-MHC independent of CD8 ( Fig. 6b) . Thus, one potential application of these enhanced affinity TCRs is for engineering CD4 + T cells to recognize and respond to the same antigen on the same tumor target as CD8 + T cells 49 . This approach could theoretically provide CD4 + T cell help and effector mechanisms to a tumor site in addition to CD8 + effector cells, which would be expected to create more potent and sustained antitumor activity 51 .
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